Food allergy
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - At least 18 years of age - Detectable IgE-sensitization to at least one of the allergens Ara h 2, 6 and 7 - Positive performed peanut food challenge for allergic patients - Negative performed peanut food challenge or convincing history for tolerant patients
Exclusion criteria
Exclusion criteria: - Pregnancy - Previously or current participation in an allergy immunotherapy trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Since this is an explorative study, the primary outcome will be divided in a discovery and a validation outcome. 1) Discovery outcomes For characterization of obtained Ara h 2, 6 and 7 specific IgE-antibodies from sensitized but tolerant and genuine allergic subjects, the epitope specificity will be examined. These outcomes will be the basis to evaluate the recognition of epitope combinations in Ara h 2, 6 and/or 7 sensitized subjects with allergy or tolerance. 2) Validation outcomes To confirm the discovery outcome, the functionality of the antibody combinations (* epitope combinations) will be investigated by loading the as relevant characterized antibody combinations on effector cells and stimulating them with the allergen of interest. The property to induce an allergic reaction will be measured by the release of mediators or the upregulation of surface maker on the effector cells. | — |
Secondary
| Measure | Time frame |
|---|---|
| Since additional parameters might influence the induction of an allergic reaction, the binding affinity of IgE antibodies and the epitope specificity of antibodies with another isotype will be measured. Their acquirement to inhibit an allergic reaction will be estimated by mediator release assay or up regulation of surface maker. Contiguous to the primary and secondary parameters, new linear and conformational epitopes may be identified. Additionally, symptoms during an allergic reaction differ between allergic subjects and the potential antibody combinations can vary accordingly. Fewtrell and Metzger, 1980, showed a greater histamine release after forming cross-linked oligomers instead of dimers [16]. Possibly, we can find hints why some subjects have stronger reactions than others. | — |
Countries
Netherlands
Outcome results
None listed